RxDoctor Payments Data

Deborah Smith

Family · Smithville, TNNPI 1598084170

Payments from drug & device makers

$3,676in general payments, 2019–2025

Across 212 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$972
  • AstraZeneca$814
  • AbbVie$546
  • Boehringer Ingelheim$155
  • Lilly USA, LLC$155
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • plus $885 from 18 others

What the payments were for

  • Food & beverage$3,676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,676 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,431
Medicare patients
70
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$53,596
OzempicSemaglutide24$38,976
FarxigaDapagliflozin Propanediol34$38,254
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$38,242
RybelsusSemaglutide16$27,860
JanuviaSitagliptin Phosphate22$18,158
TrulicityDulaglutide12$17,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,693
Xigduo XrDapaglifloz Propaned/Metformin21$11,432
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$7,892
Gabapentin70$1,843
Omeprazole95$1,609
ValacyclovirValacyclovir Hcl12$1,541
Albuterol Sulfate HfaAlbuterol Sulfate85$1,429
Levothyroxine Sodium111$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$814$76,49689 claims
Novo NordiskOzempic, Rybelsus$972$66,83640 claims
Boehringer IngelheimJardiance$155$53,59646 claims
Lilly USA, LLCTrulicity, Olanzapine$155$18,40625 claims
MerckJanuvia$18$18,15822 claims
GSKTrelegy Ellipta$44$14,69320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Smithville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →